Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis

Leukemia and Lymphoma

Volumn 52, Issue 11, 2011, Pages 2135-2138

  Malhotra, Pankaj ^a   Choudhary, Partha Prateem ^a   Lal, Vivek ^a   Varma, Neelam ^a   Suri, Vikas ^a   Varma, Subhash ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Amyloidosis; Multiple myeloma; Peripheral neuropathy; Renal failure

Indexed keywords

CREATININE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CLINICAL EXAMINATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMYELINATING NEUROPATHY; DISEASE ASSOCIATION; FEMALE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MALE; MEDICAL HISTORY; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; SEX RATIO;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; ELECTROPHYSIOLOGY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; PROSPECTIVE STUDIES;

EID: 80055008163     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.598253     Document Type: Article

References (14)

1. Silverstein A, Doniger DE. Neurological complications of myelomatosis. Arch Neurol 1963;9:534-544.
2. Sonneveld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc Hematol Educ Program 2010:423-430.
3. Delforge M, Blad é J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma:the challenge continues. Lancet Oncol 2010;11:1086-1095.
4. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007;69:573-581.
5. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy,characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518-3525.
6. Ansari-Lari MA, Ali SZ. Fine needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol 2004;30:178-181.
7. KellyJJ, Kyle RA, Miles JM. The spectrum of peripheral neuropathy in myeloma. Neurology 1981;31:24-31.
8. Vallat JM, Vital C. The spectrum of peripheral neuropathy in myeloma. Neurology 1981;31:1372-1373.
9. Camacho J, Arnalich F, Anciones B, et al. The spectrum of neurological manifestations in myeloma. J Med 1985;16:597-611.
10. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long term (<1yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74:212-216.
11. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110:1042-1049.
12. Walsh JC. The neuropathy of multiple myeloma: an electrophysiological and histological study. Arch Neurol 1971;25:404-414.
13. Latov N, Sherman WH, Nemni R, et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. N Engl J Med 1980;303:618-621.
14. Davis LE, Drachman DB. Myeloma neuropathy: successful treatment of two patients and review of cases. Arch Neurol 1972;27:507-511.